Unveiling pembrolizumab effectiveness in diverse subtypes of MSI-high endometrial cancers.
Risako OzawaTadaaki NishikawaHiroshi YoshidaKouya ShiraishiTatsunori ShimoiTomoyasu KatoKan YonemoriPublished in: Journal of gynecologic oncology (2024)
methylation cases due to its high sensitivity. Further studies are needed to determine whether EPM2AIP1 IHC can predict pembrolizumab efficacy.